Bayer stock forecast: Q4 net loss, EBITDA guidance

Bayer (BAYN) is a German life sciences company listed in Frankfurt, with its share price in focus after 4 March results showed 2026 EBITDA guidance of €9.1bn-€9.6bn and a €3.76bn Q4 net loss linked to legal provisions. Past performance is not a reliable indicator of future results.

By Dan Mitchell58 minutes ago

Photo: Shutterstock

Bayer AG (BAYN) is trading at €39.85 as of 4:01pm UTC on 10 March 2026, within an intraday range of €35.40-€39.90 on Capital.com's price feed. The last price sits near the top of today’s range but remains well below the mid-February 2026 level of around €45.80 reported in Capital.com's earlier coverage. Past performance is not a reliable indicator of future results.

The session’s move comes amid a broader recovery in German equities, with the DAX gaining approximately 2.1% on 10 March 2026 to around 23,899 (Investing.com, 10 March 2026). However, stock-specific pressure continues following Bayer’s 4 March earnings release (Bayer, 4 March 2026). The company guided 2026 adjusted EBITDA to a range of €9.1bn-€9.6bn (Investing.com, 4 March 2026). Bayer also reported a €3.76bn Q4 net loss, largely driven by legal provisions, and signalled negative free cash flow for 2026, ahead of a pending US Supreme Court review of its Roundup glyphosate litigation (Investigate Midwest, 25 February 2026). The board reiterated on 4 March that a class settlement agreement covering current and future glyphosate claims is in progress (Lawsuit Information Center, 5 March 2026), while CEO Bill Anderson described 2026 as ‘another step forward’ in the company’s five-year turnaround framework (Reuters, 4 March 2026).

Bayer stock forecast 2026–2030: Third-party price targets

As of 10 March 2026, third-party Bayer stock predictions reflect a broadly constructive but cautious stance, as brokers weigh weaker-than-expected 2026 guidance against longer-term recovery potential linked to litigation resolution and pipeline progress. The following targets summarise leading published views from February-March 2026.

mwb Research (house view, Buy-rated)

mwb Research trimmed its price target on BAYN to €52 from €54 while retaining a Buy rating, citing improved forward visibility after management clarified its 2026 earnings trajectory. The revision followed the 4 March full-year results, with the analyst pointing to currency headwinds and ongoing glyphosate provisions as the main drivers behind the adjustment (MarketScreener, 3 March 2026).

Barclays (post-results update, Overweight-rated)

Barclays reduced its price target to €48 from €50 and maintained an Overweight rating after preliminary Roundup settlement approval provided additional clarity on litigation exposure. The bank noted that 2026 EBITDA guidance implies an approximately 2-3% currency-related consensus downgrade and highlighted pharmaceuticals as potentially positioning 2026 as a trough year for sales before a projected return to mid-single-digit growth from 2027 (MarketScreener, 9 March 2026).

JPMorgan (house view, Overweight-rated)

JPMorgan maintained its Overweight rating and €50 price target. Analyst Richard Vosser described Q4 2025 results as solid, while acknowledging that the 2026 operating earnings outlook incorporates an estimated 3% currency-related consensus adjustment. The bank’s stance reflects Bayer’s multi-year restructuring plan and the possibility of resolving legacy glyphosate liabilities (The Globe and Mail, 5 March 2026).

MarketBeat (consensus overview, Moderate Buy)

MarketBeat aggregates coverage from major banks, including Barclays, Morgan Stanley and JPMorgan, and assigns BAYN a Moderate Buy consensus as of 4 March 2026. The breakdown includes two Strong Buy, four Buy, one Hold and one Sell ratings, indicating differing views on the pace of earnings normalisation and balance sheet repair (MarketBeat, 4 March 2026).

MarketScreener (broker consensus, Outperform)

MarketScreener’s consensus across 20 analysts places the average 12-month price target at €45.04, with a high estimate of €60 and a low estimate at the bottom of the published range. This equates to an implied spread of approximately +19.8% relative to the 9 March 2026 close of €37.59. The mean consensus rating stands at Outperform, with variations in assumptions around glyphosate cash outflows, currency effects and pharmaceuticals performance contributing to the dispersion (MarketScreener, 9 March 2026).

Takeaway: Individual broker targets cluster in the €48-€50 range among analysts maintaining constructive ratings, while the broader 20-analyst consensus averages €45.04. Common themes include litigation progress, currency headwinds and 2026 as a potential earnings trough.

Predictions and third-party forecasts are inherently uncertain, as they cannot fully account for unexpected market developments. Past performance is not a reliable indicator of future results.

BAYN stock price: Technical overview

The BAYN stock price trades at €39.85 as of 4:01pm UTC on 10 March 2026. The price sits just above the 10-day simple moving average (SMA) at approximately €39.45 but remains below a concentration of medium-term averages. The 20-, 50-, 100- and 200-day SMAs stand at approximately €42, €42, €36 and €32 respectively. The 20- and 50-day averages sit above the current price, while the 100- and 200-day averages remain below, marking longer-term reference levels.

Momentum indicators show limited directional extremes. The 14-day relative strength index (RSI) reads 44.7, placing it in neutral territory. The average directional index (ADX) at 33.3 indicates that a defined trend is present, although it does not signal direction.

On the upside, the first notable resistance level from classic pivot analysis lies at R1 near €47.44. A sustained move above that level would bring R2 around €52.88 into focus. The central pivot point (P) stands near €44.35 and may act as an intermediate reference if price moves higher.

On the downside, initial support appears at S1 near €38.91. Below that, the 100-day SMA around €36.37 may serve as a medium-term reference level. A move beneath this area would expose S2 near €35.81 and, further down, the 200-day SMA near €31.85 (TradingView, 10 March 2026).

This technical analysis is provided for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any instrument.

Bayer share price history (2024–2026)

BAYN’s stock price opened March 2024 around €26.80, trading within a relatively tight €25.75-€29.35 range through early April. The stock briefly reached €29.30 on 3 April before retreating. This range broadly persisted into summer 2024, with BAYN closing at €28.75 on 9 May before gradually easing lower in the second half of the year.

By November 2024, the share price had declined into the low-to-mid €20s, closing at €24.50 on 11 November. The downward trend continued into year-end, with BAYN finishing 2024 at €19.40 on 30 December.

The weakness extended into early 2025, when the stock closed at €19.05 on 3 January. A period of consolidation followed, with BAYN trading mostly between €20 and €25 during the first quarter. It reached €25.05 on 6 March before softening again in April, when it closed at €19.60 on 9 April. A gradual recovery then developed.

From mid-May 2025, the stock advanced from €22.90 on 15 May to €29.65 on 1 October, its highest level since early 2024. The recovery accelerated into the final quarter, with BAYN closing 2025 at €37.05 on 30 December.

January and February 2026 brought increased volatility. The share price climbed to a two-year closing high of €49.50 on 17 February before retreating following the 4 March earnings release. BAYN fell from €40.85 on 2 March to €35.30 on 6 March, then recovered to €39.90 by 10 March 2026. This places the stock approximately 19.5% below its 17 February peak but around 7.7% above its 30 December 2025 close.

Past performance is not a reliable indicator of future results.

Bayer (BAYN): Capital.com analyst view

Bayer’s share price has shown significant volatility over the past year, rising from the low €20s in early 2025 to €49.50 on 17 February 2026 before retracing to €39.85 by 10 March following full-year results. A proposed $7.25bn Roundup glyphosate settlement remains a central focus. If approved and upheld through the pending US Supreme Court review in the Durnell case, it could clarify future litigation exposure and reduce uncertainty around cash flows.

At the same time, Bayer expects approximately €5bn in litigation-related payments in 2026 and is guided for negative free cash flow for the year. Adjusted EBITDA guidance also fell below analyst expectations, adding pressure to near-term forecasts.

Operationally, the Pharmaceuticals division secured five pivotal approvals globally in 2025. Management outlined a pipeline across oncology, cardiology and women’s health, with a target of mid-single-digit revenue growth from 2027. The Crop Science division continues a profitability improvement programme, and the Dynamic Shared Ownership restructuring aims to deliver €2bn in cost savings. However, Xarelto faces loss of exclusivity in 2026, and Consumer Health reported softer performance in the US and China, highlighting execution risks alongside potential recovery drivers.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Past performance is not a reliable indicator of future results.

Capital.com’s client sentiment for Bayer CFDs

As of 10 March 2026, Capital.com client positioning in Bayer CFDs currently shows 96.2% of accounts holding long positions and 3.8% holding short positions, a difference of 92.4 percentage points. This snapshot reflects open positions on Capital.com at the time of capture and may change as market conditions evolve.

Summary – Bayer 2026

Bayer trades at €39.85 as of 4:01pm UTC on 10 March 2026, below its February high of €49.50 but above its January 2025 low close of €19.05.
Technical indicators present a mixed picture. The RSI at 44.7 remains neutral, with price below the 20- and 50-day SMAs but above the 100- and 200-day averages. The ADX at 33.3 signals an established trend.
Key factors under discussion include progress on the proposed $7.25bn glyphosate settlement, below-consensus 2026 EBITDA guidance and expectations for negative free cash flow.
Longer-term considerations include pharmaceuticals pipeline development and restructuring measures, alongside revenue headwinds linked to Xarelto’s loss of exclusivity and softer Consumer Health performance.

Past performance is not a reliable indicator of future results.

FAQ

Who owns the most BAYN stock?

Bayer is a widely held, publicly listed company, so ownership typically sits with a mix of institutional investors (such as asset managers and pension funds), other strategic holders, and retail shareholders. Positions can change frequently, and no single holder necessarily controls the company. If you want the most current picture, you can check Bayer’s latest shareholder disclosures and regulatory filings, which usually list major holdings once they cross relevant reporting thresholds.

What is the 5 year BAYN share price forecast?

No source can provide a reliable five-year BAYN stock forecast, and any long-range projection depends on assumptions that can change quickly. In this article, the most concrete third-party figures are 12-month analyst price targets and consensus ranges, which already show wide dispersion. Over five years, outcomes may hinge on litigation developments, cash flow, currency effects, product cycles, and execution on restructuring, among other factors.

Is BAYN a good stock to buy?

Whether BAYN is 'good' depends on your objectives, risk tolerance, and time horizon, rather than a single verdict. The article highlights potential supports, such as progress on litigation clarity and business restructuring, alongside meaningful risks, including legal uncertainty, cash flow pressure, and competitive headwinds. Instead of treating analyst ratings as instructions, you can use them as inputs and cross-check the underlying assumptions against your own research.

Could BAYN stock go up or down?

Yes. BAYN can rise or fall for company-specific reasons, such as updates on glyphosate litigation, earnings guidance, cash flow expectations, or pipeline news, and for broader market reasons, including changes in European equities, interest rates, and currency moves. The article also shows that BAYN has experienced sharp swings around events like results releases. If you trade CFDs, leverage can amplify both gains and losses, so risk management matters.

Should I invest in BAYN stock?

I can’t tell you whether you should invest. If you’re considering exposure to BAYN, you can start by defining your time horizon and maximum acceptable loss, then review key variables covered here: litigation trajectory, 2026 cash flow expectations, earnings guidance, and business segment performance. You may also want to compare multiple sources, stress-test assumptions, and consider speaking with an independent financial adviser. Capital is at risk.

Can I trade BAYN CFDs on Capital.com?

Yes, you can trade Bayer CFDs on Capital.com. Trading share CFDs lets you speculate on price movements without owning the underlying asset and to take long or short positions. However, contracts for difference (CFDs) are traded on margin, and leverage amplifies both profits and losses. You should ensure you understand how CFD trading works, assess your risk tolerance, and recognise that losses can occur quickly.